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OBJECTIVES: To evaluate exercise tolerance and the reproducibility of the six-minute walk test in Brazilian
children and adolescents with chronic kidney disease and to compare their functional exercise capacities with
reference values for healthy children.
METHODS: This cross-sectional study assessed the use of the six-minute walk test in children and adolescents
aged 6-16 with stage V chronic kidney disease. For statistical analysis of exercise tolerance, including
examinations of correlations and comparisons with reference values, the longest walked distances were
considered. The reproducibility of the six-minute walk test was assessed using intraclass correlation coefficients.
RESULTS: A total of 38 patients (14 females and 24 males) were evaluated, including 5 on peritoneal dialysis,
12 on hemodialysis and 21 who had undergone renal transplantation, with a median age of 11.2 years (6.5-16).
The median walked distance was 538.5 meters (413-685) and the six-minute walk test was found to be
reproducible. The walked distance was significantly correlated with age (r=0.66), weight (r=0.76), height
(r=0.82), the height Z score (r=0.41), hemoglobin (r=0.46), hematocrit (r=0.47) and post-test systolic blood
pressure (r=0.39). The chronic kidney disease patients predicted walked distance was 84.1% of the reference
value according to age, 90.6% according to age-corrected height and 87.4% according to a predictive equation.
CONCLUSIONS: The stage V chronic kidney disease patients had a significantly decreased functional exercise
capacity, as measured by the six-minute walk test, compared with the healthy pediatric reference values. In
addition, the six-minute walk test was shown to be well tolerated, reliable and applicable as a low-cost tool to
monitor functional exercise capacity in patients with renal disease.
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’ INTRODUCTION
The six-minute walk test (6MWT) is a submaximal test that
assesses the functional exercise capacities of healthy subjects
or those with a chronic disease, as well as the effects of inter-
ventions, such as pulmonary rehabilitation or drug therapies.
It can predict prognosis, mortality and morbidity in adults
and children with lung and/or heart diseases (1-3).
The 6MWT has been used to assess exercise tolerance in
children with chronic lung diseases, such as cystic fibrosis
(4,5) and pulmonary hypertension (6) and in those on
hemodialysis (7). Geiger et al. (8) evaluated the 6MWT in
528 healthy Caucasian children and adolescents aged 3-18
years, establishing reference values and formulating pre-
dictive equations for this population.
A study with of children with stage V chronic kidney disease
(CKD) has used the 6MWT to demonstrate decreased exercise
tolerance (9,10), which appears to be caused by several factors,
such as anemia, metabolic acidosis, electrolyte imbalance,
osteopenia, growth deficiency, malnutrition, inactivity, uremic
muscle dysfunction and associated comorbidities (11-13).
Takken et al. (12) compared the 6MWT walked distances
in Caucasian children and adolescents (8-18 years old) on
peritoneal dialysis with the reference values. These patientsDOI: 10.6061/clinics/2016(01)05
Copyright & 2016 CLINICS – This is an Open Access article distributed under the
terms of the Creative Commons License (http://creativecommons.org/licenses/by/
4.0/) which permits unrestricted use, distribution, and reproduction in any
medium or format, provided the original work is properly cited.
No potential conflict of interest was reported.
22
CLINICAL SCIENCE
exhibited a reduced exercise tolerance. The findings of this
study suggest that the 6MWT could be used as a clinical tool
to monitor functional exercise capacity in children with
kidney disease. A reduction in functional exercise capacity, as
determined using the 6MWT, has also been demonstrated in
a Brazilian study of children and adolescents aged 6-16 with
non-dialytic CKD (14).
Kohl et al. (15) evaluated 52 adult patients on hemodialysis for
12 years to determine the prognostic value of the 6MWT. They
found that the 6MWT walked distance was a mortality predictor
and verified an increase in life expectancy of approximately 5.3%
for every 100 additional meters of the walked distance.
Guillén et al. (4), Cunha et al. (5) and Gulmans et al. (16) have
demonstrated the reproducibility of the 6MWT in cystic fibrosis
patients. However, its reproducibility has not been evaluated in
pediatric CKD patients. The aims of this study were to evaluate
exercise tolerance and the reproducibility of the 6MWT in
Brazilian children and adolescents with stage V CKD and to
compare the functional exercise capacities of these patients with
internationally accepted reference values for healthy children.
’ METHODS
This cross-sectional study was approved by the human ethics
committee of Hospital das Clínicas da Faculdade de Medicina
da Universidade de São Paulo, Brazil. Written informed consent
was obtained from all subjects or their parents.
The sample size was calculated considering an alpha error
of 0.5, a sensitivity of 0.8 and a confidence interval of 95%,
demonstrating that the inclusion of at least 10 participants
was necessary, according to Rollin Brant (17).
Clinically stable children and adolescents of both genders
who were between the ages of 6-16, on peritoneal dialysis, on
hemodialysis or at least three months post-kidney transplan-
tation were included. Children with neurological, orthope-
dic, cardiac or respiratory disease were excluded, as well as
those with unstable angina and those who had suffered
myocardial infarction during the previous month, according
to the contraindications of the American Thoracic Society
(ATS) (18). The evaluation of 38 children and adolescents
with stage V CKD using the 6MWTwas performed between
July 2011 and November 2012.
All of the children and adolescents underwent anthropometric
measurements (weight and height) before participating in the
6MWT. Height and body mass index (BMI) Z scores were
calculated using WHO AnthroPlus software (19). Systolic and
diastolic blood pressure (SBP/DBP) Z scores were calculated
according to the National Institutes of Health (NIH) guidelines
(20). The 6 MWT was performed twice according to the ATS
guidelines (18), with a rest interval of 30 minutes between tests,
on a leveled 30 meter-long indoor corridor with markings at
1 meter intervals. The walked distance was measured in meters
and the test with the longest distance was selected. During the
test, the patients received standardized verbal encouragement to
walk as far as possible and they were allowed to rest if necessary,
but the chronometer was not stopped. The following measure-
ments were obtained at rest and at the end of the test: heart rate
(HR; POLARs), respiratory rate (RR; STOP WATCHs
chronometer), pulse oxygen saturation (SpO2; pulse oximeter
NONINs), blood pressure (BP; BICs aneroid sphygmoman-
ometer) and the perception of dyspnea, which was measured
using the Modified Borg Scale (21,22), with scores ranging
from 0 (no perception of dyspnea) to 10 points (maximum
perception of dyspnea).
The laboratory results for hemoglobin, hematocrit, urea,
creatinine, total calcium, ionic calcium, phosphate and
parathyroid hormone concentrations (within one month
before and after the 6MWT date) were obtained from the
medical records, as well as the dates of transplantation,
hemodialysis and peritoneal dialysis sessions.
The patients’ walked distances were compared with age–
gender reference values and with predicted walked distances
using the prediction equations of Geiger et al. (8). This compar-
ison was performed in the following three modes: with pairing
by chronological age (individuals of the same age), with pairing
by height with correction for age at the 50th percentile of the
World Health Organization (WHO) growth curve (23) and
with pairing using the walked distance predictive equation
(including sex, age and height). Statistical analysis was per-
formed using the percentages of the predicted walked dis-
tances for comparisons.
SPSS software for Windows (SPSS Inc. Release 14 standard
version) was used for statistical analysis, with a significance
level of po0.05. The test with the longest walked distance
was considered for statistical analysis and the median and
range were calculated. Spearman’s test was used to study the
correlation between the longest walked distance and age,
anthropometric measurements, hemoglobin, hematocrit and
post-test SBP. The sample characteristics did not allow for
multiple linear regression analysis.
The Mann-Whitney test was used to compare the quantitative
variables between the patient groups (transplanted and dialysis).
The intraclass correlation coefficient (ICC), standard error of
measurement and smallest detectable change assess the repro-
ducibility of the 6MWT. The Wilcoxon test was used to compare
the 6MWT measurements (at rest and at the end of the test) and
the walked distances of the study group with the age-gender
reference values. The results of this comparison are presented as
absolute values and percentages of the predicted values.
’ RESULTS
This study included 38 children and adolescents (24 males
and 14 females) with a median age of 11.2 (6.5-16) who were
on peritoneal dialysis (N=5) or hemodialysis (N=12) or had
undergone renal transplantation (N=21). The patients’
median time on dialysis and time since renal transplantation
were 2 years (1-8 years) and 2 years (5 months-4 years),
respectively. Table 1 shows the anthropometric and clinical
data of the studied population.
In this study, 50% of the population (N=19) had height
measurements that were below the third percentile for age
(WHO) (23). The post-transplant patients were significantly
taller than the dialytic patients (hemodialysis and peritoneal
dialysis; p=0.041). There were no adverse events associated
with the 6MWT and no patient needed to rest during the test.
The median longest walked distance was 538.5 m (413-685 m)
(Table 2) for the total group. Patient subgroup analysis
showed that the post-transplant participants walked a longer
distance than the dialysis patients; however, no significant
differences were detected in the other 6MWT measurements
(586 m (442-685 m) x 500 m (413-598 m), (p=0.002)).
In the present study, 12 (32%) patients, including 4 post-
transplant and 8 dialysis patients aged 6-14, demonstrated
difficulty in understanding the Modified Borg Scale for the
perception of dyspnea and were excluded from the statistical
analysis of this item.
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The walked distance on the second 6MWT was generally
longer than that of the first test (538.5 m (405-685 m) x 519.5 m
(362-674 m); po0.001), with the exception of 4 patients who
performed better on the first test. The 6MWT reproducibility
was confirmed for all variables (ICC40.4), except for the post-
test SpO2 (ICC=0.15) and pre-test dyspnea (ICC=0.13) (Table 3).
The standard error of measurement for the total group was 21.8
m and the smallest detectable change was 60.5 m. Figure 1
demonstrates the reproducibility between the first and second
6MWTs for each variable.
Our data revealed positive correlations between the longest
walked distance and age (r=0.66, po0.001), weight (r=0.76,
po0.001), height (r=0.82, po0.001), the Z score for height
(r=0.41, p=0.010), hemoglobin (r=0.46, p=0.003), hematocrit
(r=0.47, p=0.003) and post-test SBP (r=0.39, p=0.015).
Table 4 shows the walked distances of our study subjects
and those of the subjects in the Geiger et al. study (8)
according to sex and age.
As shown in Table 5, the stage V CKD patients walked
shorter distances compared with the healthy population
reference values of Geiger et al. (8) (po0.001).
’ DISCUSSION
In the present study, children and adolescents with stage V
CKD performed the 6MWT twice without adverse events,
showing that this test is a simple, quick, inexpensive, reliable
and safe method to assess functional exercise capacity in this
population, as has already been suggested in the literature (9-14).
Other alternatives for the evaluation of functional exercise capa-
city are maximal exercise tests performed on a bicycle or tread-
mill; however, such methodologies require expensive equipment.
In the present study, the youngest patients had no
difficulty in understanding or in performing the 6MWT.
Our findings are in agreement with those of Lammers et al.
(3), who assessed the 6MWT in 4- and 5-year-old children
and concluded that with clear direction and active encour-
agement as standardized by the ATS (18), this test can be
applied in this age group, with the same walked distance
variability as in older age groups.
In our study, the walked distance of the second 6MWT
was longer than that of the first test, as described in the ATS
consensus (18), reinforcing the need to perform two tests.
Table 1 - Anthropometric and clinical data for children and adolescents with stage V chronic kidney disease.
Total group (N=38) Post-transplant group (N=21) Dialysis group (N=17) p
Median (min-max)
Age (years) 11.2 (6.5-16.0) 11.4 (6.5-16.0) 10.3 (6,6-16.0) 0.913
Weight (kg) 28.6 (17.2-63.7) 33.2 (17.2-63.7) 26.0 (17.9-46.3) 0.014*
Height (m) 1.3 (0.9-1.6) 1.4 (0.9-1.6) 1.3 (1.1-1.5) 0.041*
Height (Z score) -1.9 (-5.7-1.8) -1.0 (-5.7-1.8) -2.7 (-5.5-0.7) 0.019*
BMI (kg/m2) 17.5 (13.4-27.6) 18.6 (15.3-27.6) 16.2 (13.4-24.8) 0.007*
BMI (Z score) -0.1 (-2.3-3.1) 0.4 (-1.5-3.1) -0.5 (-2.3-2.2) 0.034*
Hemoglobin (g/dL) 11.5 (7.6-15.8) 12.4 (10.0-15.8) 10.4 (7.6-13.3) 0.004*
Hematocrit (%) 34.5 (23.0-40.0) 37.0 (31.0-40.0) 33.0 (23.0-39.0) 0.029*
Urea (mg/dL) 38.0 (14.0-192.0) 35.0 (21.0-82.0) 55.0 (14.0-192.0) 0.145
Creatinine (mg/dL) 1.2 (0.4-10.6) 0.8 (0.4-1.9) 3.7 (1.7-10.6) o0.001*
Calcium (mg/dL) 9.5 (8.0-10.1) 9.5 (8.6-10.1) 9.4 (8.0-10.1) 0.263
Ionic calcium (mmol/L) 1.2 (1.0-1.4) 1.2 (1.1-1.3) 1.2 (1.0-1.4) 0.515
Phosphate (mg/dL) 4.8 (2.5-6.2) 4.9 (3.6-5.9) 4.4 (2.5-6.2) 0.167
Parathyroid hormone (pg/mL) 83.5 (3.0-1,150.0) 82.0 (3.0-211.0) 110.0 (3.0-1,150.0) 0.348
SBP (mmHg) 110 (90-140) 120 (100-130) 110 (90-140) 0.378
SBP (Z score) 1.3 (-1.1-3.6) 1.2 (-0.6-2.6) 1.3 (-1.1-3.6) 0.953
DBP (mmHg) 80 (60-90) 80 (60-90) 80 (60-90) 0.867
DBP (Z score) 1.5 (-0.5-3.0) 1.4 (-0.1-2.9) 1.7 (-0.5-3.0) 0.902
Values are expressed as the median and minimum-maximum values. BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure
* Statistically significant differences between subgroups (po0.05) (Mann-Whitney test).
Table 2 - The longest walked distance on the 6-minute walk test for stage V chronic kidney disease patients.
Total group (N=38) Post-transplant (N=21) Dialysis (N=17)
Pre Post Pre Post Pre Post
HR (bpm) 94 (70-133) 147 (111-187)* 92 (70-133) 147 (127-183)* 94 (77-130) 149 (111-187)*
SpO2 (%) 98 (95-100) 97 (94-100)* 98 (95-99) 97 (94-98)** 98 (97-100) 97 (96-100)**
SBP (mmHg) 110 (90-140) 130 (110-180)* 120 (100-130) 140 (120-180)* 110 (90-140) 130 (110-160)*
DBP (mmHg) 80 (60-90) 80 (60-110)* 80 (60-90) 80 (60-110)** 80 (60-90) 80 (60-110)**
MBP (mmHg) 90 (70-100) 100 (80-120)* 90 (70-100) 100 (90-120)* 90 (70-100) 100 (80-120)*
RR (bpm) 20 (12-28) 32 (24-44)* 20 (12-25) 32 (24-40)* 20 (16-28) 32 (24-44)*
Perception of dyspnea 0 (0-1) 2 (0-10)* 0 (0-1) 0.5 (0-10)** 0 (0-0.5) 3 (0-5)**
Walked distance (m) - 538.5 (413-685) - 586 (442-685) - 500 (413-598)w
Values are expressed as the median and minimum-maximum values; HR: heart rate in beats per minute (bpm); SpO2: pulse oxygen saturation (%);
SBP: systolic blood pressure in mmHg; DBP: diastolic blood pressure in mmHg; MBP: mean diastolic blood pressure in mmHg; RR: respiratory rate in breaths
per minute (bpm); and perception of dyspnea, determined using the Modified Borg Scale.
* Significant difference between pre- and post-6MWT (po0.001) (Wilcoxon test); **significant difference between pre- and post-6MWT (po0.05) (Wilcoxon test);
wsignificant difference between subgroups in walked distance (po0.05) (Mann-Whitney test).
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The 6MWT walked distances in the present study were
significantly shorter than the reference values for healthy
children published by Geiger et al. (8). Our dialysis patient
subgroup showed a similar walked distance on the 6MWT
(81.6% of the walked distance predicted value) compared to
that described by Takken et al. (12) (83% of the predicted
value). Although the BMI Z scores of our dialysis subgroup
were normal, other factors could have contributed to the
reduction in functional exercise capacity, such as decreased
height, anemia, a reduced renal glomerular filtration rate and
a high parathyroid hormone level.
Cury et al. (24) have demonstrated significant differences
in the 6MWT walked distance among adults in a control
group, hemodialysis group, and renal transplant group,
suggesting that renal transplantation improves this distance
without promoting full recovery of the functional exercise
capacity. These results corroborate those of the present study,
which demonstrated that renal transplantation patients
walked a longer distance compared to dialysis patients;
however, their median walked distance was still 10.5% lower
than the age-gender reference value (po0.001). In addition to
the factors that may have contributed to the low functional
exercise capacities of the CKD patients, the use of steroid
therapy for kidney transplantation immunosuppression may
also have had a negative impact on muscle fibers, resulting
in a decrease in muscle protein synthesis and impairing
oxidative metabolism (24).
Studies have shown that physical inactivity is prevalent in
the pediatric CKD population. This inactivity occurs due to
the need to avoid contact sports, a lower exercise tolerance,
anemia, vascular catheter- and arteriovenous fistula-related
restriction of physical activity and time spent on hemodia-
lysis (9-14). Most of the children in the present study did not
routinely exercise, and this may have contributed to their
poor functional exercise capacities, although physical activity
levels were not assessed in this study.
After a median walked distance of 538.5 m on the 6MWT,
the study participants exhibited increases in the HR, BP, RR
and perception of dyspnea measurements compared to the
baseline values, which is expected as a normal physiological
response related to physical exertion. These findings corro-
borate with those of Coelho et al. (14), who demonstrated
that CKD patients on conservative treatment covered a
shorter walked distance (560 m) compared with healthy
control children (724 m) and had a higher BP, RR and
Table 3 - Reproducibility of the 6-minute walk test in stage V chronic kidney disease patients.
Total group (N=38) Post-transplant (N=21) Dialysis (N=17)
6MWT 1 6MWT 2 ICC 6MWT 1 6MWT 2 ICC 6MWT 1 6MWT 2 ICC
HR pre (bpm) 94.5 (69-135) 93.5 (70-133) 0.90 93 (69-128) 92 (70-133) 0.86 95 (77-135) 94 (83-130) 0.94
HR post (bpm) 150 (111-187) 147 (110-187) 0.63 148 (122-172) 147 (127-183) 0.64 154 (111-187) 149 (110-187) 0.63
SpO2 pre (%) 98 (95-100) 98 (95-100) 0.56 98 (96-99) 98 (95-99) 0.67 98 (95-100) 98 (96-100) 0.47
SpO2 post (%) 97 (91-100) 97 (94-100) 0.15 97 (94-99) 97 (94-98) 0.32 97 (91-100) 97 (96-100) 0.08
SBP pre (mmHg) 110 (90-140) 110 (90-130) 0.75 120 (100-130) 120 (100-130) 0.70 110 (90-140) 110 (90-130) 0.78
SBP post (mmHg) 140 (110-180) 130 (110-180) 0.81 140 (120-180) 140 (120-180) 0.77 130 (110-160) 130 (110-160) 0.81
DBP pre (mmHg) 75 (60-90) 80 (60-90) 0.69 70 (60-90) 80 (60-90) 0.77 80 (60-90) 80 (60-90) 0.60
DBP post (mmHg) 80 (60-120) 80 (60-110) 0.63 80 (60-100) 80 (60-110) 0.65 80 (60-120) 80 (60-110) 0.80
RR pre (rpm) 20 (16-28) 20 (12-28) 0.51 20 (16-24) 20 (12-25) 0.25 20 (16-28) 20 (16-28) 0.77
RR post (rpm) 32 (20-44) 32 (24-44) 0.67 32 (24-44) 32 (24-40) 0.50 32 (20-44) 32 (24-44) 0.84
Dyspnea pre 0 (0-0.5) 0 (0-1) 0.13 0 (0-0.5) 0 (0-1) 0.21 0 (0-0.5) 0 (0-0.5) 0.13
Dyspnea post 3.5 (0-10) 2 (0-10) 0.57 3 (0-10) 0.5 (0-10) 0.52 4 (0-9) 3.5 (0-7) 0.73
Walked distance (m) 519 (362-674) 538.5 (405-685) 0.91 561 (382-674) 583 (442-685) 0.89 499 (362-583) 500 (405-598) 0.90
Pre- and post-6MWT values are expressed as the median and minimum-maximum values, ICC (intraclass correlation coefficient). HR: heart rate in beats per
minute (bpm); SpO2: oxygen pulse saturation (%); SBP: systolic blood pressure in mmHg; DBP: diastolic blood pressure in mmHg; RR: respiratory rate in
breaths per minute (bpm); perception of dyspnea, determined using the Modified Borg Scale; and walked distance in meters (m).
Figure 1 - Reproducibility of the walked distance between the
first and second 6-minute walk tests.
Table 4 - Distribution of stage V chronic kidney disease patients’
walked distances compared with age–gender reference values
(Geiger et al. (8)).
Sex Age category
(years)
n CKD walked
distance (m)
Walked distance
reference
value (m)
Male 6 to 8 6 496 584.0
9 to 11 5 537 667.3
12 to 15 10 625 701.1
16 3 598 727.6
Female 6 to 8 4 509 578.3
9 to 11 8 504 655.8
12 to 15 2 549 657.6
16 0 - 660.9
Values are expressed as the median.
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decreased perception of dyspnea at the end of the test.
A partial limitation of our study was the lack of a control
group, although age-gender reference values for healthy
children were used.
The 6MWT also depends on the physical effort of patients
to walk longer distances. The present study demonstrated a
correlation between the walked distance and post-test SBP
and this finding may reflect this physical effort or the
presence of a condition causing poor BP control.
According to the ATS (18) and previous studies (8,25), a
correlation exists between height and the walked distance on
the 6MWT. Multiple factors are responsible for growth
retardation in children with CKD, including persistent
metabolic acidosis, CKD-associated metabolic bone disease,
vitamin D deficiency, protein-calorie malnutrition and
hormonal alterations in the GH-IGF1 axis (26). All of these
effects may result in a lower height and shorter walked
distance on the 6MWT. In line with these studies, we
demonstrated correlations between the walked distance and
height, age and weight. A greater height usually results in
increased lower limb length, a bigger step and greater speed.
Oliveira et al. (25) have suggested that variation in the
walked distance on the 6MWT can be predicted more
accurately with an equation including the lower limb length.
Although there are no data on the positive or negative
effects of interventions on the 6MWT walked distances of
CKD pediatric patients, the present study has demonstrated
that the smallest detectable change is 60.5 m. This suggests
that a measurement of above 60.5 m in the walked distance
for this population can be considered a significant outcome.
The functional exercise capacity depends on a perfect
interaction between the respiratory and cardiovascular
systems and peripheral muscles. The hematocrit directly
influences the active transport of oxygen and carbon dioxide
in peripheral muscles and can affect the walked distance.
A study of adults on hemodialysis (the Canadian Erythro-
poietin Study Group) (27) has demonstrated that the use of
erythropoietin significantly increases the hemoglobin and
hematocrit levels but does not affect the 6MWT walked
distance. However, in our study, a correlation was found
between the walked distance and hemoglobin, as well as
between the walked distance and the hematocrit level, in
agreement with Takken et al. (12). The hemoglobin and
hematocrit levels may be important predictors of the 6MWT
walked distance for stage V CKD patients.
No differences were detected between the walked dis-
tances on the two successive tests conducted under the same
clinical conditions (Table 3, Figure 1), indicating that the
6MWT is reproducible. These results corroborate with those
of Guillen et al. (4), Cunha et al. (5) and Gulmans et al. (16),
who evaluated children with cystic fibrosis and found that
they were able to perform this test properly and repeatedly.
All of the 6MWT measurements were reproducible in this
study, except for the post-test SpO2 and pre-test perception of
dyspnea. Although significant differences were observed
between the two post-test SpO2 values, they are clinically
comparable. Despite the validation of the Modified Borg
Scale for perception of dyspnea for use in children, Morinder
et al. (28) have reported that obese children have difficulty in
understanding its use. In our study, 12 patients aged 6-14
were not able to understand this scale. We believe that this
difficulty in understanding the Modified Borg Scale may
explain the lack of reproducibility of this measurement.
Our patients’ walked distances were compared with
reference values for healthy children and adolescents accord-
ing to chronological age, according to age-corrected height
and using the walked distance predictive equation. These
three comparisons demonstrated that the stage V CKD
patients walked a shorter distance. A higher percentage
difference in the walked distance was observed in the
comparison according to chronological age, reflecting the
substantial growth retardation characteristic of CKD pediatric
patients. Significant but lower percentage differences in this
distance were detected in the comparisons according to age-
corrected height and using the walked distance predictive
equation of Geiger et al. (8), which takes into account gender,
height and age. These results suggest that growth deficit is
not the only performance-limiting factor that decreases the
walked distance of stage V CKD pediatric patients on the
6MWT. The three modes used in the present study to
compare the patients’ walked distances with reference values
from healthy children and adolescents can be useful in the
monitoring of the clinical and functional statuses of stage V
CKD patients. However, we suggest that the use of the
predictive equation may be more advantageous because it
incorporates two important variables: age and height.
In addition, the 6MWT provides important measurements
for assessments of the global and integrated responses of the
systems involved during exercise, especially HR and BP.
Most activities of daily living are performed at a submaximal
level of exertion. Thus, the submaximal test may be an
important tool for assessing the clinical and functional
statuses of stage V CKD patients. Our finding of the lower
functional exercise capacities of children and adolescents
with stage V CKD is supported by other studies in the
literature; however, the 6MWT is not routinely performed in
this patient population. We suggest that this test should be
repeated at least once a year.
We also suggest that a training program could be used for
children with stage V CKD. This training program should be
carried out and monitored by a qualified multidisciplinary
team to ensure for adequate monitoring of HR and BP,
Table 5 - Comparison of stage V chronic kidney disease patients’ median 6-minute walk test walked distances with age-gender
normative values for healthy population (Geiger et al. (8)).
Walked distance in meters and percentage of predicted value
Walked distance (m) Chronological age Age-corrected height Predictive equation
Total group 538.5 (413-685) 640.3 (84.1%)* 594.4 (90.6%)* 616.1 (87.4%)*
Post-transplant subgroup 586.0 (442-685) 653.3 (89.7%)* 629.4 (93.1%)* 636.3 (92.1%)*
Dialysis subgroup 500.0 (413-598) 639.4 (78.2%)* 596.7 (83.8%)* 612.7 (81.6%)*
Walked distance values are expressed as the median (minimum-maximum), and predicted walked distances are expressed as the median (percentage of
predicted value (%)). *Significant difference between stage V CKD patient walked distance and reference value (po0.001) (Wilcoxon test).
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implementation of arteriovenous fistula- and catheter-related
restrictions and avoidance of contact activities.
Further studies of children and adolescents with stage V
CKD should be performed to help determine the best type of
exercise, the ideal exercise intensity and the achievable
results from exercise training.
Children and adolescents with stage V CKD have
significantly poorer functional exercise capacities, as mea-
sured by the 6MWT, compared with the pediatric reference
values. This test is well tolerated and reliable, which favors
its application as a low-cost tool to monitor functional
exercise capacity in patients with renal disease.
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